Dyne Therapeutics Q3 net loss widens on higher trial costs
DYN•Dyne Therapeutics reported a third-quarter net loss of $193.55 million, missing the $172.01 million analyst estimate, as manufacturing and clinical trial costs increased. The company expects potential U.S. launches of z-rostudirsen in Q1 2027 and z-basivarsen in H1 2028, pending regulatory approvals.
1. Quarterly results
Dyne Therapeutics’ third-quarter net loss was $193.55 million, compared with an analyst estimate of $172.01 million. Its operating loss was $197.07 million, also missing the $175.27 million estimate. The company attributed higher research and development expenses mainly to increased manufacturing for z-rostudirsen and clinical trial costs for the FORZETTO and HARMONIA Phase 3 trials; higher general and administrative expenses reflected launch preparations, including increased headcount.
2. Pipeline outlook
Dyne expects potential U.S. approval and launch of z-rostudirsen in Q1 2027. It expects topline data from the ACHIEVE REC trial of z-basivarsen in Q1 2027 and a potential U.S. launch in H1 2028, pending regulatory approval.
